BRAF V600EPhase 3 RCTNat Med 2025來源:人工整理

EC+mFOLFOX6 vs SOC (1L)

關鍵結果ORR 60.9% vs 40.0%, OR 2.44

BREAKWATER 首報:一線 EC+化療 ORR 達 61%,FDA 加速核准

詳細證據整理

Encorafenib, Cetuximab and Chemotherapy in BRAF-Mutant Colorectal Cancer: A Randomized Phase 3 Trial

Authors: Kopetz S, Yoshino T, Kim TW, et al.
Journal: Nature Medicine 2025;31:901-908
DOI: 10.1038/s41591-024-03443-3
PMID: 39863775 | PMCID: PMC11922750
Study: BREAKWATER (Phase 3, ORR Primary Analysis and First OS Interim Analysis)
Retrieved from PubMed Central (PMC)

Abstract

Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC. The dual primary endpoint of progression-free survival is event driven; data were not mature at data cutoff. BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403-4.253; 99.8% CI: 1.019-5.855; one-sided P = 0.0008). Median duration of response was 13.9 versus 11.1 months. At this first interim analysis of overall survival, the hazard ratio was 0.47 (95% CI: 0.318-0.691; repeated CI: 0.166-1.322). Serious adverse event rates were 37.7% versus 34.6%. The safety profiles were consistent with those known for each agent. BREAKWATER demonstrated a significantly improved response rate that was durable for first-line EC+mFOLFOX6 versus SOC in patients with BRAF V600E mCRC.

Introduction

V600E mutations occur in 8-12% of metastatic colorectal cancers (mCRCs); the presence of these mutations has emerged as a distinct subtype that is characterized by poor prognosis compared with wild-type disease and resistance to standard chemotherapy regimens. V600E mutations are found in multiple tumor types, and BRAF inhibitors in combination with MEK inhibitors are part of the standard of care (SOC) in BRAF-mutant melanoma and non-small cell lung cancer.

Encorafenib is a highly selective, ATP-competitive small-molecule BRAF inhibitor with anti-proliferative and apoptotic activity in tumor cells expressing V600E and has prolonged pharmacodynamic activity compared with other approved BRAF inhibitors. BRAF V600E inhibition causes rapid pathway feedback reactivation through the epidermal growth factor receptor (EGFR); previous clinical trials targeting BRAF simultaneously with EGFR inhibition have shown the value of this combination in targeting MAPK signaling. Encorafenib plus cetuximab, an anti-EGFR monoclonal antibody, is approved for previously treated BRAF V600E-mutant mCRC based on results from the BEACON study. Median overall survival was 8.4 months, the objective response rate was 20%, median progression-free survival was 4.2 months and no new safety signals were observed with encorafenib plus cetuximab.

Despite this promising option of targeted treatments in the second and later lines as demonstrated in the BEACON study, first-line chemotherapies with or without a biologic agent (eg, bevacizumab) have had limited efficacy for BRAF V600E-mutant mCRC. Furthermore, the addition of bevacizumab with doublet and triplet chemotherapy has been debated due to tolerability concerns. There are currently no first-line activation pathway-targeted treatments indicated for patients with BRAF V600E-mutant mCRC; therefore, a treatment that can demonstrate improved efficacy in the first-line setting is needed given the poor prognosis compared with BRAF wild-type mCRC.

BREAKWATER is a phase 3 study evaluating encorafenib plus cetuximab with or without standard chemotherapy (mFOLFOX6) versus SOC, investigator's choice of chemotherapy (mFOLFOX6; FOLFOXIRI; or CAPOX) with or without bevacizumab for the first-line treatment of patients with BRAF V600E-mutant mCRC. Data from the safety lead-in portion demonstrated encouraging response rates and progression-free survival of encorafenib and cetuximab with chemotherapy (mFOLFOX6 or FOLFIRI).

Reported here are one of the dual primary endpoints, objective response rate and the first interim analysis of overall survival, duration of response, time to response and safety in the EC+mFOLFOX6 and SOC arms from the phase 3 portion. The second dual primary endpoint, progression-free survival, is event driven; the required number of events needed for analysis had not yet been achieved at the time of writing and will be reported later.

Results

Patients

Patients were enrolled between 16 November 2021 and 22 December 2023 in the phase 3 portion of the study. Eligible patients had previously untreated BRAF V600E-mutant mCRC in the metastatic setting, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Eastern Cooperative Oncology Group performance status 0-1. 236 patients were randomized to the EC+mFOLFOX6 arm and 243 were randomized to the SOC arm in the phase 3 portion of the study. At data cutoff (22 December 2023), study treatment was ongoing in 137 patients in the EC+mFOLFOX6 arm and 82 in the SOC arm.

Baseline demographics and disease characteristics were similar across arms. The median age was 61 years, 49.5% of patients were female and 42.0% of patients had an ECOG performance status of 1. The majority of patients had tumors that were on the right (61.0%), and most were microsatellite stable/proficient mismatch repair (95.2%).

Treatment

The median duration of treatment was 28.1 weeks (range: 1.3-107.4) in the EC+mFOLFOX6 arm and 20.4 weeks (range: 1.1-98.3) in the SOC arm.

Efficacy

Objective Response Rate (Primary Endpoint): In the objective response rate subset of all randomized patients, the dual primary endpoint of confirmed objective response rate by blinded independent central review was met (60.9% [95% CI: 51.6-69.5] versus 40.0% [95% CI: 31.3-49.3] in the EC+mFOLFOX6 and SOC arm, respectively; odds ratio = 2.443 [95% CI: 1.403-4.253; 99.8% CI: 1.019-5.855], one-sided P = 0.0008).

Endpoint EC+mFOLFOX6 (n=236) SOC (n=243)
Confirmed ORR (BICR) 60.9% (95% CI 51.6-69.5) 40.0% (95% CI 31.3-49.3)
Odds Ratio 2.443 (99.8% CI 1.019-5.855), P=0.0008
Median TTR 7.1 weeks 7.3 weeks
Median DOR 13.9 months (95% CI 8.5-NE) 11.1 months (95% CI 6.7-12.7)
DOR ≥6 months 68.7% 34.1%
DOR ≥12 months 22.4% 11.4%

Predefined subgroup analyses of objective response rate showed consistency in results across all key clinical subgroups, including regardless of presence of liver metastases.

Overall Survival (Key Secondary Endpoint - First Interim Analysis): Upon achieving the dual primary endpoint of objective response rate, the key secondary endpoint of overall survival was formally tested. The median overall survival follow-up was 10.3 months (95% CI: 8.6-11.6) in the EC+mFOLFOX6 arm and 9.8 months (95% CI: 7.5-11.3) in the SOC arm. At this interim analysis, 40 (16.9%) deaths had occurred in the EC+mFOLFOX6 arm and 72 (29.6%) deaths in the SOC arm. The overall survival hazard ratio was 0.47 (95% CI: 0.318-0.691; repeated CI: 0.166-1.322); statistical significance was not achieved at this time. The median overall survival was not estimable (95% CI: 19.8 to NE) versus 14.6 months (95% CI: 13.4-NE), respectively. The landmark overall survival rates were 92.3% versus 87.1% at 6 months and 79.5% versus 66.1% at 12 months.

Safety

Treatment-emergent adverse events occurred in 99.6% versus 97.8% of patients in the EC+mFOLFOX6 arm versus SOC arm, respectively.

The most frequent (≥30%) treatment-emergent adverse events were:

Adverse Event EC+mFOLFOX6 SOC
Nausea51.1%48.2%
Anemia36.4%22.8%
Diarrhea34.2%46.9%
Decreased appetite33.3%25.0%
Vomiting33.3%21.1%
Neutrophil count decreased32.0%28.1%

Grade 3/4 adverse events occurred in 74.0% of patients in the EC+mFOLFOX6 arm versus 61.0% in the SOC arm. Grade 5 (fatal) adverse events occurred in 4.3% versus 4.4% of patients, respectively; grade 5 treatment-related adverse events occurred in 0% versus 0.4% of patients, respectively. Serious treatment-emergent adverse events occurred in 37.7% versus 34.6%. Adverse events leading to permanent discontinuation of any study intervention occurred in 20.8% versus 14.9%.

Discussion

BREAKWATER has met one of its dual primary endpoints, objective response rate, demonstrating a statistically significant and clinically relevant benefit in objective response rate by blinded independent central review with EC+mFOLFOX6 versus SOC. At the time of this analysis, data also showed a point estimate of overall survival hazard ratio of 0.47 for EC+mFOLFOX6 versus SOC; however, 16.9% of patients in the EC+mFOLFOX6 arm and 29.6% of patients in the SOC arm had an event at data cutoff for this first interim analysis and did not achieve the prespecified statistical significance.

Secondary endpoints showed the response to EC+mFOLFOX6 was rapid and durable. The percentage of patients with a duration of response beyond 6 or 12 months approximately doubled in the EC+mFOLFOX6 arm compared with the SOC arm. These early overall survival data showed a clear separation between the arms in the Kaplan-Meier curves.

Trials of chemotherapy plus cetuximab or bevacizumab, BRAF inhibitor monotherapy, BRAF inhibitors with MEK inhibitors, and BRAF inhibitors with chemotherapy have shown limited benefit over the current SOC for patients with BRAF V600E-mutant mCRC. These data highlight the importance of combining dual targeted therapy (encorafenib and cetuximab) with chemotherapy in BRAF V600E-mutant CRC to improve patient outcomes in the first-line setting.

Safety data showed that EC+mFOLFOX6 was generally tolerable, with a safety profile consistent with that known for each agent. Patients in the EC+mFOLFOX6 arm had a longer duration of treatment and maintained high relative dose intensities.

BREAKWATER excluded patients with MSI-H or dMMR tumors unless ineligible to receive immune checkpoint inhibitors due to a preexisting medical condition. SEAMARK is an ongoing phase 2 study evaluating first-line EC with pembrolizumab versus pembrolizumab alone in patients with BRAF V600E-mutant and MSI-H/dMMR mCRC.

Methods

Trial Design and Treatment

Patients were randomized 1:1:1 to the EC arm (encorafenib 300 mg orally once daily; cetuximab 500 mg/m² intravenously once every 2 weeks), EC+mFOLFOX6 arm (encorafenib 300 mg orally once daily; cetuximab 500 mg/m² intravenously once every 2 weeks; oxaliplatin 85 mg/m² intravenously, leucovorin 400 mg/m² intravenously, and 5-FU 400 mg/m² intravenous bolus, then 5-FU 2400 mg/m² continuous intravenous infusion over 46-48 h, all once every 2 weeks [mFOLFOX6; 28-day cycle]) or investigator's choice SOC arm (mFOLFOX6 with or without bevacizumab; FOLFOXIRI with or without bevacizumab; CAPOX with or without bevacizumab). Following a protocol amendment, enrollment to the EC arm was stopped and patients were randomized 1:1 to the EC+mFOLFOX6 or SOC arms.

Randomization stratification factors were ECOG performance status (0 versus 1) and region (US/Canada versus Europe versus Rest of World).

Endpoints

The dual primary endpoints are objective response rate and progression-free survival by blinded independent central review between the EC+mFOLFOX6 and SOC arms, to be evaluated independently. The key secondary endpoint is overall survival between the EC+mFOLFOX6 and SOC arms.

Statistical Analysis

The sample size of 235 patients per arm was determined based on statistical assumptions for progression-free survival analysis. An overall one-sided alpha of 0.024 was unequally divided between the two dual primary endpoints. Objective response rate was analyzed in the objective response rate subset (first 110 patients randomized per arm). This sample size of 220 patients provided 90% power to test the odds ratio at a one-sided alpha of 0.001, assuming ORR of 35% and 65% for the SOC and EC+mFOLFOX6 arms, respectively.

Updated PFS/OS data available in: Elez E et al. N Engl J Med 2025. DOI: 10.1056/NEJMoa2501912

本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。

讀者討論

讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。

載入留言中…

  • GuidelineJNCCN 2026來源:摘要

    NCCN Colon Cancer v3.2026(Guidelines Insights)

    BRAF V600E 晚期治療推薦更新, 晚期治療章節依 biomarker 重組; 新增 fluoropyrimidine 前 DPYD 檢測; 依近期試驗更新非轉移性輔助治療

    NCCN 結腸癌 v3.2026 依 biomarker 重組晚期治療章節,並特別更新 BRAF V600E 推薦,承接 BREAKWATER 證據;另新增化療前 DPYD 檢測建議。Insights 摘要未列推薦等級,細節需對照指引全文

  • Phase 3 (Cohort 3)ASCO GI 2026來源:人工整理

    EC+FOLFIRI vs FOLFIRI±bev (1L)

    ORR 64.4% vs 39.2%, OR 2.76; 肝 mets ORR 79.1%

    FOLFIRI 也行——提供第二個化療骨幹選擇,特別適合 oxaliplatin 禁忌

  • Biomarker (exploratory)ESMO 2025來源:人工整理

    EC+mFOLFOX6 vs EC vs SOC

    C2D15 D/ND: 67.1% vs 45.2% vs 37.5%; resistance 6.6% vs 37.9%

    化療骨幹壓制抗藥性克隆——EC+chemo 優於 EC alone 的分子機制

  • Phase 3 RCT (updated)NEJM 2025來源:人工整理

    EC+mFOLFOX6 vs SOC (1L)

    mPFS 12.8 vs 7.1 mo; mOS 30.3 vs 15.1 mo, HR 0.49

    mOS 30.3 個月——BRAF V600E mCRC 首次追上 BRAF wt 的存活。死亡風險減半

看 BRAF V600E 的全部文獻